NASDAQ : CAPR
Capricor Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.63 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 385.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 370.93M |
| Enterprise Value | 224.04M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 58.14M |
| Shares Outstanding | 58.14M |
| Shares Change (YoY) | +24.20% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 60.87% |
| Float | 45.55M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 6.55 |
| PB Ratio | 1.51 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.35 |
| Quick Ratio | 7.22 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.38 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -73.70% |
| Return on Assets (ROA) | -33.63% |
| Return on Invested Capital (ROIC) | -38.11% |
| Return on Capital Employed (ROCE) | -40.25% |
| Weighted Average Cost of Capital (WACC) | 6.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$560,245 |
| Employee Count | 231 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1,600 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -7.80% |
| 50-Day Moving Average | 8.06 |
| 200-Day Moving Average | 20.77 |
| Relative Strength Index (RSI) | 41.54 |
| Average Volume (20 Days) | 2,762,670 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19.86M |
| Short Previous Month | 18.83M |
| Short % of Shares Out | 34.16% |
| Short % of Float | 43.61% |
| Short Ratio (days to cover) | 5.50 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -99.73M |
| Operating Income | -135.16M |
| Pretax Income | -129.41M |
| Net Income | -129.42M |
| EBITDA | -133.07M |
| EBIT | -135.16M |
| Earnings Per Share (EPS) | -$2.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 237.93M |
| Total Debt | 91.05M |
| Net Cash | 146.89M |
| Net Cash Per Share | $2.53 |
| Equity (Book Value) | 246.22M |
| Book Value Per Share | 4.24 |
| Working Capital | 209.17M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -104.00M |
| Capital Expenditures | -25.78M |
| Depreciation & Amortization | 2.09M |
| Net Borrowing | n/a |
| Free Cash Flow | -129.78M |
| FCF Per Share | -$2.23 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -24.20% |
| Shareholder Yield | -24.20% |
| Earnings Yield | -38.65% |
| FCF Yield | -34.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $27.00 |
| Price Target Difference | 323.20% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 5, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |